WO2004047871A3 - Modified naturetic compounds, conjugates, and uses thereof - Google Patents

Modified naturetic compounds, conjugates, and uses thereof Download PDF

Info

Publication number
WO2004047871A3
WO2004047871A3 PCT/US2003/037996 US0337996W WO2004047871A3 WO 2004047871 A3 WO2004047871 A3 WO 2004047871A3 US 0337996 W US0337996 W US 0337996W WO 2004047871 A3 WO2004047871 A3 WO 2004047871A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
compounds
modified
disclosed
natriuretic
Prior art date
Application number
PCT/US2003/037996
Other languages
French (fr)
Other versions
WO2004047871A2 (en
Inventor
Kenneth D James
Balasingam Radhakrishnan
Navdeep B Malkar
Mark A Miller
Nnochiri N Ekwuribe
Original Assignee
Nobex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobex Corp filed Critical Nobex Corp
Priority to BR0316560-4A priority Critical patent/BR0316560A/en
Priority to EP03812053A priority patent/EP1569683B1/en
Priority to CA002504287A priority patent/CA2504287A1/en
Priority to AT03812053T priority patent/ATE459370T1/en
Priority to AU2003297583A priority patent/AU2003297583B2/en
Priority to DE60331584T priority patent/DE60331584D1/en
Priority to JP2004555809A priority patent/JP2006515579A/en
Publication of WO2004047871A2 publication Critical patent/WO2004047871A2/en
Publication of WO2004047871A3 publication Critical patent/WO2004047871A3/en
Priority to HK06107556.5A priority patent/HK1087327A1/en
Priority to AU2010201455A priority patent/AU2010201455A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)

Abstract

Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, subcutaneous, and intravenous forms to of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the natriuretic compound are also disclosed, having an amino acid sequence that is other than the native sequence.
PCT/US2003/037996 2002-11-26 2003-11-12 Modified naturetic compounds, conjugates, and uses thereof WO2004047871A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BR0316560-4A BR0316560A (en) 2002-11-26 2003-11-12 Natriuretic Compound Conjugate, Pharmaceutical Formulation, Method of Treating a Condition, Method of Preparing the Natriuretic Compound Conjugate, Modified Pro-Polynatriuretic Peptide Conjugate, Natriuretic Peptide Analog, hbnp Analogue, Compound, and Method of Preparing a Compound
EP03812053A EP1569683B1 (en) 2002-11-26 2003-11-12 Modified natriuretic compounds, conjugates, and uses thereof
CA002504287A CA2504287A1 (en) 2002-11-26 2003-11-12 Natriuretic compounds, conjugates, and uses thereof
AT03812053T ATE459370T1 (en) 2002-11-26 2003-11-12 MODIFIED NATRIURETIC COMPOUNDS, CONJUGATES AND USES THEREOF
AU2003297583A AU2003297583B2 (en) 2002-11-26 2003-11-12 Modified naturetic compounds, conjugates, and uses thereof
DE60331584T DE60331584D1 (en) 2002-11-26 2003-11-12 MODIFIED NATRIURETIC COMPOUNDS, CONJUGATES, AND ITS USES
JP2004555809A JP2006515579A (en) 2002-11-26 2003-11-26 Natriuretic compounds, conjugates, and uses thereof
HK06107556.5A HK1087327A1 (en) 2002-11-26 2006-07-04 Modified natriuretic compounds, conjugates, and uses thereof
AU2010201455A AU2010201455A1 (en) 2002-11-26 2010-04-13 Modified natriuretic compounds, conjugates, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42915102P 2002-11-26 2002-11-26
US60/429,151 2002-11-26

Publications (2)

Publication Number Publication Date
WO2004047871A2 WO2004047871A2 (en) 2004-06-10
WO2004047871A3 true WO2004047871A3 (en) 2005-03-17

Family

ID=32393512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/037996 WO2004047871A2 (en) 2002-11-26 2003-11-12 Modified naturetic compounds, conjugates, and uses thereof

Country Status (13)

Country Link
US (1) US7662773B2 (en)
EP (1) EP1569683B1 (en)
JP (1) JP2006515579A (en)
CN (1) CN100558398C (en)
AT (1) ATE459370T1 (en)
AU (2) AU2003297583B2 (en)
BR (1) BR0316560A (en)
CA (1) CA2504287A1 (en)
DE (1) DE60331584D1 (en)
HK (1) HK1087327A1 (en)
PL (1) PL377813A1 (en)
SG (1) SG159387A1 (en)
WO (1) WO2004047871A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662773B2 (en) 2002-11-26 2010-02-16 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US9102707B2 (en) 2011-08-30 2015-08-11 Mayo Foundation For Medical Education And Research Natriuretic polypeptides

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524635B2 (en) * 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
WO2004022003A2 (en) * 2002-09-06 2004-03-18 University Of South Florida Materials and methods for treatment of allergic diseases
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US20060110359A1 (en) * 2002-09-06 2006-05-25 Juan Sanchez-Ramos Cellular delivery of natriuretic peptides
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
EP1660047B1 (en) 2003-08-13 2013-11-27 Biocon Limited Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
EP1727556A2 (en) * 2004-02-17 2006-12-06 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
PL3404102T3 (en) 2004-04-21 2021-12-13 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
ATE496060T1 (en) 2004-07-15 2011-02-15 Univ Queensland PROTEIN-TYPE COMPOUNDS AND APPLICATIONS THEREOF
US20080207505A1 (en) * 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
US7300494B2 (en) * 2005-02-24 2007-11-27 Hamilton Sundstrand Corporation On-board inert gas generation system with compressor surge protection
WO2006110743A1 (en) 2005-04-07 2006-10-19 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure
ES2529258T3 (en) 2005-07-29 2015-02-18 Nektar Therapeutics Methods for preparing polymer reagents
WO2007035600A2 (en) * 2005-09-16 2007-03-29 Mayo Foundation For Education And Research Natriuretic activities
WO2007047834A2 (en) * 2005-10-18 2007-04-26 Biocon Limited Oral peptide conjugates for metabolic diseases
EP2004633A4 (en) 2006-03-30 2009-08-26 Palatin Technologies Inc Linear natriuretic peptide constructs
BRPI0709427A2 (en) 2006-03-30 2011-07-12 Palatin Technologies Inc "Cyclic construct, pharmaceutical composition and use of a compound
WO2007127487A2 (en) * 2006-04-28 2007-11-08 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
WO2008019187A2 (en) 2006-05-30 2008-02-14 Mayo Foundation For Medical Education And Research Detecting and treating dementia
DK2037948T3 (en) 2006-05-30 2016-08-01 Mayo Foundation Detection and treatment of dementia
WO2007143561A1 (en) 2006-06-01 2007-12-13 Mayo Foundation For Medical Education And Research Immunity to folate receptors
WO2008088582A2 (en) 2006-08-04 2008-07-24 Mayo Foundation For Medical Education And Research Methods and materials related to trail isoforms
JP2010502231A (en) 2006-09-08 2010-01-28 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Aquatic and natriuretic polypeptides lacking vasodilatory action
JP2010523714A (en) 2007-04-12 2010-07-15 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Ischemia / reperfusion protection composition and method of use
KR20080098216A (en) * 2007-05-04 2008-11-07 한미약품 주식회사 Natriuretic peptide conjugate using carrier substance
AU2008326327A1 (en) 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
WO2009156481A1 (en) * 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
WO2010033216A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of nesiritide peptides
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
MX2011012277A (en) 2009-05-20 2011-12-12 Biomarin Pharm Inc Variants of c-type natriuretic peptide.
US20120108514A1 (en) 2009-07-09 2012-05-03 University Of Iowa Research Foundation Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
BR112012001491B1 (en) 2009-07-23 2022-03-15 Igisu Co., Ltd Therapeutic preparation for treating dermatitis and use of a therapeutic preparation
WO2011136744A1 (en) 2010-04-27 2011-11-03 Agency For Science, Technology And Research Eif4e binding peptides
WO2012013597A1 (en) * 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Substances and the use thereof for influencing natriuretic peptide receptors
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
WO2012115772A2 (en) 2011-02-25 2012-08-30 Medtronic, Inc. Therapy for kidney disease and/or heart failure
CN103402542B (en) 2011-02-28 2017-05-03 独立行政法人国立循环器病研究中心 Medicinal agent for inhibiting metastasis of malignant tumor
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
JP6038795B2 (en) 2011-08-19 2016-12-07 国立研究開発法人国立循環器病研究センター Pharmaceutical for preventing exacerbation of malignant tumor comprising a combination of natriuretic peptide receptor GC-A agonist and GC-B agonist
EP2750697A4 (en) 2011-09-02 2015-03-25 Medtronic Inc Chimeric natriuretic peptide compositions and methods of preparation
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
CN107266554A (en) * 2012-03-19 2017-10-20 麦德林制药私人有限公司 Method, expression construct, host cell and the recombinant fusion polypeptide of Prepare restructuring blood vessel dilatation peptide
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
TW201442721A (en) * 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd Glycosilated atrial natriuretic peptide
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
RU2708068C2 (en) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Treating convulsions using recombinant alkaline phosphatase
JP6868561B2 (en) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド How to treat subjects with alkaline phosphatase deficiency
CA2986086A1 (en) * 2015-05-29 2016-12-08 Igisu Co., Ltd. Cyclyc peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide
CN108350440A (en) 2015-08-17 2018-07-31 阿雷克森制药公司 The manufacture of alkaline phosphate ester
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
IL293979B1 (en) 2016-01-08 2024-04-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
SG11201805026SA (en) * 2016-01-08 2018-07-30 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low npr-c binding
WO2017118707A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
EP3400020A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
PL3400019T3 (en) * 2016-01-08 2023-01-23 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
CA3007982C (en) * 2016-01-08 2023-12-19 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3436052A4 (en) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (en) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド How to treat bronchomalacia
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
SG10202111952PA (en) 2016-09-29 2021-12-30 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
EP3538131A4 (en) 2016-11-09 2020-07-01 Mayo Foundation for Medical Education and Research Manp analogues
BR112019019720A2 (en) * 2017-03-22 2020-04-28 Pharmain Corp npra agonists, compositions and uses thereof
US11224637B2 (en) 2017-03-31 2022-01-18 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
US11547760B2 (en) 2017-09-05 2023-01-10 Torque Therapeutics, Inc. Reversible linkers and use thereof
CN111432836A (en) 2017-09-05 2020-07-17 转矩医疗股份有限公司 Therapeutic protein compositions and methods of making and using same
EP3770143A4 (en) 2018-03-20 2021-12-22 NOF Corporation Branched monodispersed polyethylene glycol, intermediate, and method for producing same
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
KR102022118B1 (en) * 2019-01-07 2019-09-18 주식회사 아스트로젠 Serine derivative compound for the prevention or treatment of centralnervous system diseases
CN110278941B (en) * 2019-07-11 2021-05-28 西安国际医学中心有限公司 Isolated heart protection solution containing natriuretic peptide
CN111978390B (en) * 2020-08-31 2022-10-14 上海景泽生物技术有限公司 Polyethylene glycol modified rhBNP and application thereof
CN111848776B (en) * 2020-08-31 2022-03-18 江苏璟泽生物医药有限公司 Polyethylene glycol modified rhBNP and preparation method thereof
WO2023039392A1 (en) * 2021-09-07 2023-03-16 Mayo Foundation For Medical Education And Research Methods and materials for determining pgc target dosage
CN114316020A (en) * 2021-12-28 2022-04-12 南京岚煜生物科技有限公司 BNP recombinant protein, preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295679A2 (en) * 1987-06-17 1988-12-21 Daiichi Pure Chemicals Co. Ltd. Physiologically-active novel peptides
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
US6162902A (en) * 1996-03-04 2000-12-19 Scios Inc. Human BNP-specific antibodies
WO2000078302A1 (en) * 1999-06-19 2000-12-28 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same
WO2002098446A1 (en) * 2001-06-04 2002-12-12 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044196A (en) * 1972-03-30 1977-08-23 Bayer Aktiengesellschaft Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
AU8762982A (en) * 1981-07-02 1983-02-02 Walton, A.G. Glycosaminoglycan drug complexes
ATE37983T1 (en) * 1982-04-22 1988-11-15 Ici Plc DELAYED RELEASE AGENT.
US4569794A (en) * 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5037741A (en) * 1986-08-18 1991-08-06 The Coca Cola Company Enzymatic method for the synthesis and separation of peptides
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
JP2539665B2 (en) * 1988-06-20 1996-10-02 日本臓器製薬株式会社 Neurological drug
JP2561513B2 (en) 1988-07-04 1996-12-11 塩野義製薬株式会社 Monoclonal antibody that recognizes γ-ANP
JPH0720857B2 (en) 1988-08-11 1995-03-08 テルモ株式会社 Liposome and its manufacturing method
IT1229514B (en) 1989-01-30 1991-09-03 Farmhispania S A A Montme SYNTHETIC AMPHIPHILIC GLYCOCONUGATES FOR NEUROLOGICAL USE.
EP0385476B2 (en) 1989-03-01 1999-09-22 SHIONOGI & CO., LTD. Physiologically active polypeptide and DNA
US20020086843A1 (en) 1989-03-01 2002-07-04 Daiichi Pure Chemicals Co., Ltd. Physiologically active polypeptide and DNA
JP3394040B2 (en) 1989-06-23 2003-04-07 ジェネンテック・インコーポレーテッド Compositions and methods of synthesis and use of natriuretic protein receptor B
US5108568A (en) * 1989-07-07 1992-04-28 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Controlled method of reducing electrophoretic mobility of macromolecules, particles or cells
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
SE8904407L (en) 1989-12-29 1991-06-30 Qingpingfeng MEDICATION FOR TREATMENT OF HEART FAILURE
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5202239A (en) 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
JP3026354B2 (en) 1990-09-27 2000-03-27 壽之 松尾 Human CNP gene and precursor protein
US5853746A (en) 1991-01-31 1998-12-29 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier
ATE253639T1 (en) 1991-08-19 2003-11-15 Daiichi Suntory Pharma Co Ltd METHOD FOR PRODUCING PEPTIDES
JP2665850B2 (en) 1991-11-14 1997-10-22 塩野義製薬株式会社 Monoclonal antibody recognizing the C-terminus of hBNP
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
CA2188143A1 (en) 1992-12-09 1995-11-02 Wolf-Georg Forssmann Use of brain natriuretic peptides (bnp), phosphorylated urodilatine, phosphorylated cdd/anp and combinations thereof
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5512459A (en) * 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
WO1995006467A1 (en) 1993-08-28 1995-03-09 The University Of Sheffield Treatment of laminitis
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US6037145A (en) 1994-09-07 2000-03-14 Suntory Limited Process for production of protein
NO319913B1 (en) * 1994-12-09 2005-10-03 Shionogi & Co Procedure for sandwich immunoassay for N-peptide
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
AU730969B2 (en) 1995-10-19 2001-03-22 University Of Washington Discrete-length polyethylene glycols
US6407060B1 (en) 1996-03-22 2002-06-18 Curis, Inc. Method for enhancing functional recovery following central nervous system ischemia or trauma
ZA979060B (en) 1996-10-22 1999-04-09 Genentech Inc Receptor selective BNP
US6028055A (en) 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
AU6820898A (en) 1997-04-04 1998-10-30 Novo Nordisk A/S Natriuretic peptide derivatives
US20040005669A1 (en) * 1997-08-07 2004-01-08 Stefan Stahl Recombinant expression of insulin C-peptide
GB9716790D0 (en) 1997-08-07 1997-10-15 Creative Peptides Sweden Ab Recombinant DNA molecules comprising multimeric copies of a gene sequence and expression thereof
US6013630A (en) 1997-08-21 2000-01-11 Curagen Corporation Atrial natriuretic factor mutants and ischemic stroke
DE69830668T3 (en) 1997-10-24 2011-07-14 Shionogi & Co., Ltd. PROCESS FOR INHIBITING THE DEGRADATION OF NATRIURETIC PEPTIDES AND IMPROVED METHOD FOR DETERMINING THE NATRIURETIC PEPTIDES
US6495514B1 (en) * 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
IL138214A0 (en) * 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6117644A (en) * 1998-06-04 2000-09-12 Ottawa Heart Institute Research Corporation Predicting and detecting cardiac allograft rejection
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
SE9802946D0 (en) 1998-09-02 1998-09-02 Europrofil Ab Procedures and moldings to cover joints or make transitions in connection with coatings
JP3799465B2 (en) * 1998-09-28 2006-07-19 参天製薬株式会社 Eye drops for promoting lacrimal secretion or treating keratoconjunctival disorders containing natriuretic peptide as an active ingredient
DE60000288T2 (en) 1999-01-26 2003-01-16 Lilly Co Eli MONODISPERSE FORMULATIONS CONTAINING HEXAMERS ACYLATED INSULIN ANALOGS
DK1105409T3 (en) * 1999-05-17 2006-07-03 Conjuchem Inc Protection of endogenous therapeutic peptides from peptidase activity by conjugation with blood components
AU5043900A (en) 1999-05-24 2000-12-12 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
KR100345214B1 (en) * 1999-08-17 2002-07-25 이강춘 The nasal transmucosal delivery of peptides conjugated with biocompatible polymers
US6610043B1 (en) * 1999-08-23 2003-08-26 Bistech, Inc. Tissue volume reduction
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US7127290B2 (en) 1999-10-01 2006-10-24 Cardiac Pacemakers, Inc. Cardiac rhythm management systems and methods predicting congestive heart failure status
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
JP4237375B2 (en) * 2000-03-31 2009-03-11 アスビオファーマ株式会社 Pharmaceutical composition used for treatment or prevention of ischemic disease
TWI249519B (en) * 2000-08-29 2006-02-21 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US20030219734A1 (en) * 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
FR2823993B1 (en) * 2001-04-27 2003-06-20 Rhodia Chimie Sa STABLE AQUEOUS COLLOIDAL DISPERSION, PREPARATION METHOD THEREOF
DE60235416D1 (en) * 2001-05-04 2010-04-01 Biosite Inc Diagnostic markers of acute coronary syndromes and their uses
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6737913B2 (en) * 2001-06-15 2004-05-18 Silicon Laboratories, Inc. Differential mode circuitry and method of calibrating same without matched external current sources
JP4318546B2 (en) 2001-09-07 2009-08-26 バイオコン・リミテッド Method for synthesizing insulin polypeptide-oligomer conjugate, and proinsulin polypeptide-oligomer conjugate and method for synthesizing the same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
WO2003081246A1 (en) * 2002-03-18 2003-10-02 Scios Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
JP2006514607A (en) 2002-07-31 2006-05-11 コンジュケム，インコーポレーテッド Long-lasting sodium excretion increasing peptide derivative
AU2003285200A1 (en) 2002-11-09 2004-06-03 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
AU2003297583B2 (en) 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
US20060198819A1 (en) * 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295679A2 (en) * 1987-06-17 1988-12-21 Daiichi Pure Chemicals Co. Ltd. Physiologically-active novel peptides
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
US6162902A (en) * 1996-03-04 2000-12-19 Scios Inc. Human BNP-specific antibodies
WO2000078302A1 (en) * 1999-06-19 2000-12-28 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same
WO2002098446A1 (en) * 2001-06-04 2002-12-12 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANG T K ET AL: "Subtiligase: a tool for semisynthesis of proteins.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 20 DEC 1994, vol. 91, no. 26, 20 December 1994 (1994-12-20), pages 12544 - 12548, XP002280083, ISSN: 0027-8424 *
CONDON, J. AM. OIL. CHEM. SOC., vol. 71, no. 7, 1994, pages 739 - 741, XP001181312 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662773B2 (en) 2002-11-26 2010-02-16 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US9102707B2 (en) 2011-08-30 2015-08-11 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US9441027B2 (en) 2011-08-30 2016-09-13 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US9587004B2 (en) 2011-08-30 2017-03-07 Mayo Foundation For Medical Education And Research Natriuretic polypeptides

Also Published As

Publication number Publication date
EP1569683A2 (en) 2005-09-07
CN100558398C (en) 2009-11-11
WO2004047871A2 (en) 2004-06-10
US7662773B2 (en) 2010-02-16
EP1569683B1 (en) 2010-03-03
DE60331584D1 (en) 2010-04-15
PL377813A1 (en) 2006-02-20
CA2504287A1 (en) 2004-06-10
BR0316560A (en) 2005-10-04
JP2006515579A (en) 2006-06-01
AU2003297583A1 (en) 2004-06-18
CN1741814A (en) 2006-03-01
AU2010201455A1 (en) 2010-05-06
HK1087327A1 (en) 2006-10-13
SG159387A1 (en) 2010-03-30
AU2003297583B2 (en) 2010-01-14
ATE459370T1 (en) 2010-03-15
US20040203081A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
WO2004047871A3 (en) Modified naturetic compounds, conjugates, and uses thereof
WO2005116655A3 (en) Natriuretic compounds, conjugates, and uses thereof
WO2006076471A3 (en) Bnp conjugates and methods of use
JP5990506B2 (en) Insulin drug conjugates using immunoglobulin fragments
US20150274801A1 (en) Acylated glucagon analogues
WO2005058958A3 (en) Novel glp-1 analogues linked to albumin-like agents
US20180371045A1 (en) Novel insulin derivatives
KR101330868B1 (en) Insulin derivative drug conjugate using an immunoglobulin fragment
JP2017078078A (en) Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate
BRPI1014416B1 (en) NEW EXENDINA AND CONJUGATE VARIANTS
JP2008500375A5 (en)
TWI747929B (en) An acylation derivative of human insulin or analog thereof
EP2264065A3 (en) Novel Insulin Derivatives
RU2009105696A (en) N-END POLYSIAL
WO2007056362A3 (en) Glucagon analogs exhibiting physiological solubility and stability
IL199247A (en) Oxyntomodulin derivative peptides, pharmaceutical compositions comprising the same and uses thereof for affecting feeding behavior
RU2014129893A (en) PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT OF HUMAN DISEASES ASSOCIATED WITH HUMAN GROWTH
CA2755395A1 (en) Method for preparing a site-specific physiologically active polypeptide conjugate
KR101679612B1 (en) An improved process for preparation of physiologically active polypeptide complex
MX2009002999A (en) Protease resistant insulin analogues.
CA2608311A1 (en) Glp-1 pegylated compounds
EP2022505A3 (en) GLP-1, exendin-4, peptide analogs and uses thereof
WO2009158704A3 (en) Therapeutic agents comprising elastin-like peptides
HK1049016B (en) C-peptide for the improved production of insulin and insulin analogues
EP2275439A3 (en) Novel insulin derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2504287

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003297583

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 999/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 377813

Country of ref document: PL

Ref document number: 2004555809

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003812053

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038A91794

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003812053

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0316560

Country of ref document: BR